

Virtual Event for Clients on 2020 NMBP Calls – 25th October 2019

FAQs V.1 – 11th November 2019

General Questions

1. What place do toxicity testing, hazard assessment have in calls focusing on applications of nanotechnology? Are there any budget requirements from the total project budget envisioned for this?

There are no specific budget requirements, the distribution of the requested contribution is left to proposers to determine and justify.

2. We are interested in 3 calls from H2020 calls (NMBP, Transport and FET). Can we apply as coordinator in 3 calls? Do we have an application limit?

You can, there is no limit (but of course the same work can be funded only once).

3. Some of the calls state that proposal should include social science and humanities dedicated WPs. What are the expectations from the EC regarding social science inclusion in the NMBP calls?

The human side in general is becoming an important aspect, which can help enhance impact – the purpose is not simply to provide funding to SSH practitioners. The requirements depend on the particular topic and should be clear from the scope and expected impacts of the topic. As a general principle, the SSH contributions should be closely integrated with the other work of the project, and able to influence its direction.

4. Can the December 12th date for submission of stage 1 proposals for 2 stage calls be moved out by at least one week?

No, deadlines and evaluations are planned well in advance, and deadlines are delayed only in exceptional circumstances (e.g. if there is an IT issue).

5. Opportunities for international participants?

Other than topic BIOTEC-08-2020, which requires cooperation with Chinese partners, the 2020 topics of the NMBP part do not have explicit provisions but are open to international cooperation, based on the standard rules of Horizon 2020. International cooperation may be particularly appropriate e.g. in some SPIRE areas but not only.

6. How can we meet partners to build a consortium?

One way of finding potential partners is from each call topic, which includes a facility for finding partners who have expressed an interest in the topic.

You can use matchmaking online platforms such as [NMPTeAm online Partner Search tool](#) specifically addressed to consortia building for the NMP calls, [EEN](#) specifically addressed to SMEs and [CORDIS](#) regarding H2020 projects.

Another way to find partners is by consulting projects that were already funded or members of [European Technology Platforms](#) and Private Associations ([EFFRA](#), [A.SPIRE](#), [E2B](#), etc).

Moreover, you can also check the brokerage events already organized by [NMPTeAm](#), [EFFRA](#), etc.

7. Some SPIRE topics have a rather high budget per project (eg. > 10 M€). Is the expectation that the consortia will be made up of a big number of partners?

This is possible but not necessary. The relatively large recommended budget is due to the significant demonstration activities expected (at relevant scale) and the expected costs of the demonstrators needed.

8. Is there any matchmaking platform?

There are several matchmaking platforms.
Please check answer to question number 6.

9. Are there any specific information material available for the PPPs topics, like SPIRE, to better understand the context and background of the topics?

It may be useful for proposers to consult the roadmaps and other information on the website of each PPP:

<https://www.effra.eu/factories-future>
<https://www.spire2030.eu/intro>
<http://www.ectp.org/>

10. Where can we find / obtain all the calls mentioned in the presentation?

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/programmes/h2020>

11. Are there calls that specifically preview collaboration with Canada on medical topics?
12. Are there calls where Korean partners are targeted?

No (not in 2020), but please see also the answer on international cooperation in general.

NB: In the Health part of the WP, there is a 2020 topic envisaging cooperation with Japan or Canada: SC1-DTH-04-2020 "International cooperation in smart living environments for ageing people"

13. Can we talk about success rate?

It is impossible to predict the success rates in the 2020 calls. In the 2019 calls, success rates were around 15% (35% in the 2nd-stage of two-stage calls). Please also note that the budget in 2020 is higher than in 2019.

NMBP-21-2020

14. there is a reference to the following call: "SC1-HCO-19-2020: Reliable and accessible information on cell and gene-based therapies". Is it possible to clarify the envisaged links/synergies with this future CSA? How consortia can deal with this criteria in the proposals?

This reference is provided only for the proposers' information and there are no a priori obligations at the proposal stage. The selected projects under the respective calls may be encouraged to exchange information.

15. The propositions should start at TRL 3 and reach TRL 5. However in order to meet the expected impact, it seems important to also produce clinical data sets (so as to demonstrate health cost reductions). Consequently can the proposed projects integrate clinical trials phase 1 (TRL 6) or is it out of scope?

Yes, Phase-1 clinical trials (TRL 6) can be addressed at the limit, provided that they are needed for the project research. However, the core of the research should span TRLs from 3 to 5.

16. "Proposals should cover one of the following domains: • Targeted musculoskeletal delivery of cells or biologically active agents and innovative biomaterials for articular cartilage/disc, ligament and tendon repair in weight-bearing joints", Should the proposal reply to all problematics "articular cartilage/disc, ligament and tendon repair"? Or can it reply only to (e.g.) "articular cartilage/disc"?

+ Could you confirm that is it necessary to cover the 3 lines described in the project scope? technically seems not possible.

While proposals should pursue one of the domains introduced by bullet points in the scope, *if the 1st domain is selected*, then all three aspects in that domain must be covered, namely articular cartilage/disc, ligament and tendon repair in weight-bearing joints.

17. In scope section, fourth bullet : "...planned in respect of the foregoing". The word "foregoing" refers to the previous three bullets or the previous part of call?

It refers to the three previous bullets, i.e., if the 4th domain is selected, then the innovative manufacturing should address one of the three 'foregoing' domains.

NMBP-23-2020: Next generation organ-on-chip (RIA-LS).

18. In Next generation organ-on-chip topic (DT-NMBP-23-2020), scope includes: "Taking into account medical regulatory requirements". In your opinion would it be advisable to have a partner expert in regulatory testing?

The topic calls for regulatory requirements to be taken into account, and this could be done by including a dedicated partner, but other possibilities could also be envisaged.

19. If one Work Package is not completed must the correspondent part paid in the pre-financing be returned to the EC?

In this hypothetical scenario, the Commission will withhold the payment corresponding to the work package that is not delivered; this may ultimately result in a recovery order, depending also on the previous pre-financing. But for more specific information on this topic, please refer to EC's enquiry service:

https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service-and-participant-validation_en.

20. The scope text, the relation to the topic “SC1-BHC-11-2020: Advancing the safety assessment of chemicals without the use of animal testing” is highlighted but not explained. We would like to understand what is expected.

This reference is provided only for the proposers' information and there are no a priori obligations at the proposal stage. The selected projects under the respective calls may be encouraged to exchange information.

21. The initiative ORCHID – Organ on chip in development (CSA, FET-OPEN) is closing. Can you clarify the possible relations between ORCHID and the TOPIC DT-NMBP-23-2020? Were the output of ORCHID taken in consideration for the description and expectations of NMBP-23 topic?

The ORCHID project (ORgan-on-CHip In Development) creates a roadmap for organ-on-chip technology and the framework to build a network of relevant stakeholders. The DT-NMBP-23-2020 topic has its own specific challenge, scope and expected impact. In particular, projects are expected to reach TRL 5.

22. The proposed technology should apply to a broad range of life science sectors, including medicine and pharmacy, cosmetics, agriculture and food, and for chemical safety testing. Are there priorities?

No, these areas are mentioned as examples of where the technologies to be developed would be useful.

23. What is expected number of partners in NMBP-16-2020?

There are no requirements in this respect, other than the absolute minimum of three partners. Please note that the recommended funding is 6-8M€, which is a typical level for a Research and Innovation Action.

SPIRE-07 – Preserving fresh water: recycling industrial water industry

24. Is it enough to focus on one industrial sector or must one address multiple ones?

The presence of several sectors is not an eligibility criterion and therefore it is possible to submit proposals including only one sector. It is important to consider the topic text and align the proposals to the scope and expected impacts, and to show clearly how the proposed solution can solve the challenge put forward. Industrial Symbiosis is clearly mentioned in the challenge as an enabler for greatly enhanced resource and energy efficiency, so this should be carefully considered in the context of the proposals.

SPIRE-08-2020 – Novel high performance materials and components (RIA)

25. Are there any target market pre identified? Aeronautics, space or any other production process?

The targeted process industry is to be identified in the proposal. [Aeronautics and space may be marginal areas, because they are not energy-intensive process industries.]

26. “Reduction of environmental impacts in terms of waste management and energy and resource consumption” can this be reflected as materials repair, reuse and recycling?

These could be examples of the expected reduction of environmental impacts.

27. In the call text is written: “With a view to future processes to be identified, the proposed solutions **across value chains should** demonstrate at least two out of following three impacts:” Can you clarify what is expected with across value chains?

In this case, ‘across value chains’ refers to the process industries that each proposal targets, i.e. demonstrate at least two out of the three impacts in all targeted process industries.

28. expected impact: “Energy efficiency improvement of the target production and/or operation processes of at least 30%;” it refers to the process and not to the product, right?

Right!

29. How many projects are expected to be funded?

The number of funded projects is not fixed in advance, but please note that the indicative budget of the topic is 32.5M€ and that the recommended funding per project is 4-6M€.

DT-NMBP-05-2020: Open Innovation Test Beds for materials for building envelopes (IA)

30. Could we better specify the expected impact listed in the call: "At least 20 % improved industrial process parameters and 30% faster verification of materials performance for highly promising applications and at least 30% reduction in energy consumption across the entire life cycle"?

The process parameters are those associated with the production, e.g. energy and resource consumption, cost and rate of production.